Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
View original at finance.yahoo.comNovo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts Quick Read Novo Nordisk (NVO) cut Wegovy and Ozempic prices up to 48% in India due to generic semaglutide competition, while shares have fallen 43% over the past year to $36.98 as 2026 guidance signals -5% to -13% adjusted sales growth; the c…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
CagriSema (cagrilintide plus semaglutide) is expected to receive FDA obesity decision around end of 2026/early 2027
60% confidence2026 guidance signals -5% to -13% adjusted sales growth
60% confidencePhase 3 data showed 14.2% weight loss in type 2 diabetes patients for CagriSema
60% confidenceWegovy HD achieved an average weight loss of 20.7% over 72 weeks
60% confidence
Data points we hold from this source
| Novo Nordisk · stock price 52 week low | 35.12 USD |